For example, Cai et al. reported that isorhamnetin inhibits the proliferation and metastasis of androgen-independent prostate cancer cells by targeting the endogenous apoptotic pathway and selectively inhibiting PI3K/AKT/mTOR signalling [40]. This evidence concerns the gene MTOR and prostate carcinoma.